Across TCGA pan-cancer cohorts, LINC02221 RNA differs between tumor and matched normal tissue in 1 of 18 cancer types tested, making tumor–normal expression one of LINC02221’s most consistent transcriptional readouts.
The strongest signal is observed in breast invasive carcinoma (BRCA), where LINC02221 RNA is more highly expressed in tumor relative to normal tissue. In most cancer types LINC02221 is over-expressed in tumor.
BRCA are the cancer types where LINC02221 tumor–normal differential expression is most reproducible.